Onco Wiki / Bandeira vermelha

CML with T315I gatekeeper mutation in the BCR-ABL1 kinase domain — resistant to all 1st/2...

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDRF-CML-T315I-MUTATION
TipoSinal de alerta
Estadoreviewed 2026-04-25 | pending_clinical_signoff
DoençasDIS-CML
FontesSRC-ELN-CML-2020 SRC-NCCN-MPN-2025

Origem da bandeira vermelha

DefiniçãoCML with T315I gatekeeper mutation in the BCR-ABL1 kinase domain — resistant to all 1st/2nd-gen TKIs; requires ponatinib or asciminib (STAMP)
Direcção clínicaintensificar
Categoriahigh-risk-biology
Algoritmo de deslocamentosALGO-CML-1L

Lógica de Desencadeamento

{
  "any_of": [
    {
      "finding": "bcr_abl_t315i",
      "value": true
    },
    {
      "finding": "kinase_domain_mutation",
      "value": "T315I"
    }
  ],
  "type": "biomarker"
}

Notas

T315I emergence on imatinib / 2nd-gen TKI mandates switch to ponatinib (full-dose 45 mg → response-adjusted to 15 mg per OPTIC) or asciminib STAMP (response rates ~50% in T315I-positive). Both NOT registered in Ukraine — major access barrier. AlloHCT remains alternative for fit patients without ponatinib/asciminib access. Mandatory kinase-domain resistance mutation screening at TKI failure or suboptimal response per ELN 2020 milestones. STUB — requires clinical co-lead signoff.

Usado por

Algoritmos

Indicação